Amryt Pharma Sustainability Profile
Amryt Pharma, a biopharmaceutical company headquartered in Ireland (IE), is dedicated to developing innovative treatments for rare and complex diseases. Founded in 2015, Amryt has rapidly established itself in the industry, focusing on areas such as dermatology and metabolic disorders. The company’s flagship products, including AP101 for epidermolysis bullosa and AP103 for other dermatological conditions, are distinguished by their unique formulations and targeted delivery mechanisms. Amryt Pharma has achieved significant milestones, including successful product launches and strategic partnerships, positioning itself as a leader in the rare disease market. With a commitment to improving patient outcomes, Amryt continues to expand its global reach, making a meaningful impact in the lives of those affected by challenging health conditions.
DitchCarbon Score
How does Amryt Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amryt Pharma's score of 69 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Amryt Pharma's reported carbon emissions
In 2023, Amryt Pharma reported total carbon emissions of approximately 980,116,000 kg CO2e. This figure includes 29,906,000 kg CO2e from Scope 1 emissions, 591,000 kg CO2e from Scope 2 emissions, and a significant 949,619,000 kg CO2e from Scope 3 emissions. The total emissions for 2022 were slightly lower at about 928,102,000 kg CO2e, with Scope 1 emissions at 29,715,000 kg CO2e, Scope 2 emissions at 822,000 kg CO2e, and Scope 3 emissions at 897,564,000 kg CO2e. Amryt Pharma's emissions data is cascaded from its parent company, Chiesi Farmaceutici S.p.A., reflecting a corporate family relationship. However, there are currently no specific reduction targets or climate pledges disclosed by Amryt Pharma. The company is part of an industry context that increasingly prioritises sustainability and carbon footprint reduction, yet it has not publicly committed to Science-Based Targets Initiative (SBTi) reduction targets or other formal climate initiatives. Overall, Amryt Pharma's emissions profile highlights the significant impact of Scope 3 emissions, which constitute the majority of its carbon footprint, indicating a need for comprehensive strategies to address emissions across its value chain.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 33,911,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 15,835,000 | 0,000,000 | 000,000 | 000,000 |
| Scope 3 | 742,267,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Amryt Pharma's Industry?
How Carbon Intensive is Amryt Pharma's Location?
Amryt Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Amryt Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
